Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 737 results for "continuous renal replacement therapy"

Biomarkers of Inflammation during Continuous Renal Replacement Therapy: Sensors, Players, or Targets A Reply to the Letter by Villa et al.
Sexual Development

Biomarkers of Inflammation during Continuous Renal Replacement...

General Please address all your queries or problem reports to the Pay-per-View Customer Service at info@karger.com referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ... Sexual Development, 5 days ago

1 images for "continuous renal replacement therapy"

Sexual Development, 5 days ago

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study

by Yong Kyu Lee, Hae Won Lee, Kyu Hun Choi, Beom Seok Kim Continuous renal replacement therapy (CRRT) is considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care units (ICUs).
 Plosone.org1 week ago
Drug Discovery World

Effects of Renal Replacement Therapy on Renal Recovery after Acute Kidney Injury

Recovery of kidney function following an episode of acute kidney injury (AKI) is now acknowledged as a vital patient-centered outcome with clear health economic implications. In approximately 5-8% of critically ill patients with more severe forms of ...
 Sexual Development4 weeks ago Targeting Recovery from Acute Kidney Injury: Executive Summary from the Round Table Conference at the 19th International Conference on Continuous Renal Replacement Therapies (Manchester Grand Hyatt, San Diego, Calif., USA, March 2-3, 2014)  Sexual Development4 weeks ago Developing the first treatment for Acute Kidney Injury. Spring 14  Drug Discovery World1 month ago

Preview: FDA September 17 Adcom On Testosterone Replacement Therapy

Summary The FDA is set to hold a joint meeting of the Bone, Reproductive and Urologic Drugs and the Drug Safety and Risk Management Advisory Committees on Sep. 17. The purpose of the meeting is to discuss the appropriate population for ...
 Seeking Alpha1 month ago

Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011

Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR) Additional GL-3 Data Further Validate Assay for Identifying Patients with Amenable Mutations CRANBURY, N.J., and SAN DIEGO, ...
 Market Pulse Navigator2 days ago Amicus Therapeutics, Inc. Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011  BioSpace2 days ago Amicus Therapeutics : Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011  4 Traders2 days ago Amicus announces positive data from Phase III Fabry disease study  Individual.com1 month ago
[x]  

Rockwell Medical Announces FDA Advisory Committee Review of Triferic for the Treatment of Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients

WIXOM, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) -- . (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron ...
 Pettinga Financial Advisors1 week ago Rockwell Medical, Baxter Healthcare join forces  Drug Discovery News2 weeks ago Rockwell Medical : Announces FDA Advisory Committee Review of Triferic for the Treatment of Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients  4 Traders1 week ago Rockwell Medical Receives $8 Million in Cash Via Exercise of Warrants  Individual.com2 weeks ago
[x]  

Amicus Therapeutics' (FOLD) CEO John Crowley on Phase III Fabry Monotherapy Study Results (Transcript)

Operator Good day, ladies and gentlemen, and welcome to the Amicus Phase 3 Fabry monotherapy results conference call. At this time all participants are in a listen only mode. Later we will conduct a question-and-answer session and instructions ...
 Seeking Alpha2 months ago

Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with ...
 Pettinga Financial Advisors1 month ago (PR) Merck Receives Accelerated Approval of KEYTRUDA(R) (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy  Scottrade1 month ago MERCK : Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy  4 Traders1 month ago Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014  CEOWorld Magazine3 weeks ago
[x]  

ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

"Bayer's presence at this global medical congress demonstrates our commitment to research in the oncology space, as we continue to explore additional treatment options and further investigate the clinical candidates in our franchise portfolio," said ...
 Morningstar.com4 weeks ago AMGEN : ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise  4 Traders4 weeks ago
[x]  

Novartis' : investigational heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in PARADIGM-HF trial

LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment regimen for HF-REF 1 Study showed significantly more HF-REF patients on LCZ696 regimen were alive ...
 4 Traders1 month ago Novartis' investigational heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in PARADIGM-HF trial  Red Orbit1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less